N/A
Completed N=60
Fundus Findings and Thiol-Disulfide Homeostais
Source: ClinicalTrials.gov NCT05958927 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcomePrimary: Glucose Levels of the Groups in Pregnant Women With Impaired Blood Sugar and/or Gestational DM — 111.67; 154; 83.06; 88.15 mg/dl
Summary
Gestational diabetes mellitus is associated with abnormal blood sugar levels throughout pregnancy in women without prior diabetes. Many studies have been conducted on the relationship between diabetes and oxidative stress. In this study, it was aimed to investigate the presence of fundus findings in patients with gestational diabetes and/or impaired blood sugar based on the results of previous studies and to simultaneously investigate the thiol-disulfide homeostasis in the tears of the patients.There was no previous study in the literature on thiol disulfide homeostasis in tears in gestational diabetic patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glucose Levels of the Groups in Pregnant Women With Impaired Blood Sugar and/or Gestational DM |
111.67; 154; 83.06; 88.15 | — |
| SECONDARY Retinal Nerve Fiber Thickness and Macular Thickness in Pregnant Women With Impaired Blood Sugar and/or Gestational DM |
101.91; 100.23; 123.82; 124.85; 132.59; 128.23 | — |
| SECONDARY Oxidative Stress Level in Pregnant Women With Impaired Blood Sugar and/or Gestational DM |
13.96; 2.31; 34.75; 19.76; 10.76; 8.75 | — |
| SECONDARY Retinal Nerve Fiber Temporal Quadrant Thickness in Pregnant Women With Impaired Blood Sugar and/or Gestational DM |
80.53; 70.81; 72.12; 72.27; 123.82; 124.85 | — |
Eligibility Criteria
Example:
Inclusion Criteria
- Healthy pregnant at 24-28 weeks of pregnancy
- Pregnant patients diagnosed with gestational diabetes and/or impaired blood sugar at 24-28 weeks of pregnancy
Exclusion Criteria
- Type 1diabetes mellitus,
- Type 2 diabetes mellitus,
- Patient that history of ocular surface disease,
- Topical/systemic medical therapy with ocular inflamatuar disease such as üveitis.
Data sourced from ClinicalTrials.gov (NCT05958927). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.